Tampa, Florida
Welcome,         Profile    Billing    Logout  
 5 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hauser, Robert
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated
3
7
Europe, US
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
07/23
07/23
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
522
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
06/24
06/24
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Active, not recruiting
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
10/24
02/25
LUMA, NCT05348785 / 2021-004849-20: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort

Recruiting
N/A
4500
Europe, Canada, US, RoW
Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders
Parkinson Disease
12/33
12/33
Benbadis, Selim
NCT04244175: A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Completed
2
154
Europe, US, RoW
CVL-865, Placebo
Cerevel Therapeutics, LLC
Seizures
05/24
05/24
NCT05473442: Study of EQU-001 for Uncontrolled Focal Onset Seizures

Terminated
2
27
US, RoW
EQU-001, Matching Placebo
Equilibre Biopharmaceuticals B.V.
Focal Onset Seizures
07/23
07/23
NCT06705439: A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning (USF)

Recruiting
N/A
50
US
Nelli
Neuro Event Labs Inc.
Epilepsy
06/25
06/25
NCT04526418: Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients With Epilepsy Involving the Temporal Lobe Region.

Recruiting
N/A
110
Europe, US
24/7 EEG™ SubQ system
UNEEG Medical A/S
Epilepsy
09/25
04/26
Henninger, Heidi
NCT04244175: A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Completed
2
154
Europe, US, RoW
CVL-865, Placebo
Cerevel Therapeutics, LLC
Seizures
05/24
05/24
NCT05473442: Study of EQU-001 for Uncontrolled Focal Onset Seizures

Terminated
2
27
US, RoW
EQU-001, Matching Placebo
Equilibre Biopharmaceuticals B.V.
Focal Onset Seizures
07/23
07/23
Washington, Kadijah
SIGNAL-AA, NCT06018428: Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata

Active, not recruiting
2
40
US
ADX-914, Placebo
Q32 Bio Inc., Innovaderm Research Inc.
Alopecia Areata
12/24
12/24

Download Options